| Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool AK Pathak, M Bhutani, S Kumar, A Mohan, R Guleria Clinical chemistry 52 (10), 1833-1842, 2006 | 294 | 2006 |
| Targeting Mcl-1 for the therapy of cancer BA Quinn, R Dash, B Azab, S Sarkar, SK Das, S Kumar, RA Oyesanya, ... Expert opinion on investigational drugs 20 (10), 1397-1411, 2011 | 249 | 2011 |
| Biomarkers in cancer screening, research and detection: present and future: a review S Kumar, A Mohan, R Guleria Biomarkers 11 (5), 385-405, 2006 | 168 | 2006 |
| Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance AA Bhat, SN Younes, SS Raza, L Zarif, S Nisar, I Ahmed, R Mir, S Kumar, ... Molecular cancer 19, 1-21, 2020 | 101 | 2020 |
| A common medical error: lung cancer misdiagnosed as sputum negative tuberculosis VK Singh, S Chandra, S Kumar, G Pangtey, A Mohan, R Guleria Asian Pac J Cancer Prev 10 (3), 335-8, 2009 | 97 | 2009 |
| Effect of change in symptoms, respiratory status, nutritional profile and quality of life on response to treatment for advanced non-small cell lung cancer A Mohan, P Singh, S Kumar, C Mohan, AK Pathak, RM Pandey, R Guleria Asian Pac J Cancer Prev 9 (4), 557-62, 2008 | 65 | 2008 |
| Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy S Kumar, R Guleria, V Singh, AC Bharti, A Mohan, BC Das Lung Cancer 70 (2), 211-217, 2010 | 58 | 2010 |
| Urine miRNA signature as a potential non-invasive diagnostic and prognostic biomarker in cervical cancer M Aftab, SS Poojary, V Seshan, S Kumar, P Agarwal, S Tandon, V Zutshi, ... Scientific reports 11 (1), 10323, 2021 | 57 | 2021 |
| Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer S Kumar, R Guleria, V Singh, AC Bharti, A Mohan, BC Das European Respiratory Journal 36 (4), 885-892, 2010 | 53 | 2010 |
| Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non–small cell lung cancer patients S Kumar, SK Sharawat, A Ali, V Gaur, PS Malik, S Kumar, A Mohan, ... Current problems in cancer 44 (4), 100540, 2020 | 51 | 2020 |
| Epigenetic regulators of programmed death-ligand 1 expression in human cancers S Kumar, SK Sharawat Translational Research 202, 129-145, 2018 | 51 | 2018 |
| Prognostic implications of circulating anti‐p53 antibodies in lung cancer–a review S Kumar, A Mohan, R Guleria European Journal of Cancer Care 18 (3), 248-254, 2009 | 48 | 2009 |
| Plasma nucleosome levels might predict response to therapy in patients with advanced non–small-cell lung Cancer S Kumar, R Guleria, V Singh, AC Bharti, A Mohan, BC Das Clinical lung cancer 11 (1), 36-44, 2010 | 33 | 2010 |
| Role of microRNAs in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer M Pandey, A Mukhopadhyay, SK Sharawat, S Kumar Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1876 (1), 188552, 2021 | 32 | 2021 |
| Efficacy of plasma TGF-β1 level in predicting therapeutic efficacy and prognosis in patients with advanced non-small cell lung cancer S Kumar, R Guleria, A Mohan, V Singh, AC Bharti, BC Das Cancer Investigation 29 (3), 202-207, 2011 | 31 | 2011 |
| Association of functionally important polymorphism of microsomal epoxide hydrolase gene (EPHX1) with lung cancer susceptibility AR Tilak, S Kumar, M Jain, MC Pant, BC Das, R Guleria, B Mittal, ... Cancer Investigation 29 (6), 411-418, 2011 | 29 | 2011 |
| PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix M Mann, S Kumar, A Sharma, SS Chauhan, N Bhatla, S Kumar, S Bakhshi, ... Oncotarget 10 (42), 4262, 2019 | 24 | 2019 |
| Differential expression of circulating serum miR-1249-3p, miR-3195, and miR-3692-3p in non-small cell lung cancer S Kumar, SK Sharawat, A Ali, V Gaur, PS Malik, M Pandey, S Kumar, ... Human Cell 33, 839-849, 2020 | 21 | 2020 |
| Molecular signature of postmortem lung tissue from COVID-19 patients suggests distinct trajectories driving mortality A Budhraja, A Basu, A Gheware, D Abhilash, S Rajagopala, S Pakala, ... Disease Models & Mechanisms 15 (5), dmm049572, 2022 | 20 | 2022 |
| Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer S Kumar, R Guleria, V Singh, AC Bharti, A Mohan, BC Das BMC cancer 9, 1-12, 2009 | 20 | 2009 |
